biomed devic servic
biomed devic servic
price close busi april
diabet time covid thought
interest report season
given unpreced impact throughout economi near-term
expect everi compani cover obvious significantli alter
origin expect come report period evid
seen across med-tech saw host pre-announc busi
updat almost result warn uncertain near-term revenu
guidanc withdrawn diabetes-focus compani appear
first glanc rel insul given diabet deferr advanc
technolog use within diabet definit deferr survey result
past week show new patient visit declin significantli april
expect drawn-out recoveri last least
earn ramp next week report
felt opportun time revisit estim price target
continu expect rel ok relat current
expect albeit without upsid mani investor come expect
sub-industri origin survey result march suggest almost half
endocrinologist realli feel impact covid second week
march anoth feel impact third week month
interestingli diabet sector cover seen pre-announc
suspens guidanc
robust instal base provid floor execut view
instal base recur revenu natur podd/dxcm busi model
rel insul given patient alreadi activ user pumps/cgm
theoret lower custom support train requir
new patient volum like challeng near-term dramat
chang expect steep drop patient volum most-
recent endocrinologist survey result indic expect april volum
may june improv slowli drop
respect survey result also indic expect rebound take
week success flatten curv expect volum remain
suppress least expect new cgm pump adopt like drop
meaning show modest q/q improv expect
volum normal time late
telemedicin help training/support still burden without in-person
resourc telemedicin use heavili make differ patient
visit howev equal import virtual train custom support new cgm/
pump user survey suggest ok still lag in-person train
effect point april survey show respond felt access
support/train impact new patient adopt felt impact
exist patient util dynam believ impact pump
cgm given higher train program burden pump carri
import monitor go forward given efficaci remot train
physician confid efficaci key maintain new patient adopt
period social distanc said expect materi acceler
easier comp year headwind becom next year tailwind
canaccord genuiti global capit market group canaccord genuiti group inc cf tsx
recommend opinion express research report accur reflect research analyst person independ object
view compani secur subject report discuss herein
import inform pleas see import disclosur begin page document
biomed devic servic
cost key barrier adopt pumps/cgm said survey work
indic macro uncertainti impact patient dynam specif
cite out-of-pocket spend main factor new exist
patient look addit insight upcom result call
acknowledg shift pharmaci channel dxcm/podd may chang
dynam addit price advantag pharmaci shift also remov multipl
layer insur author test requir dme channel expect
compani benefit dynam rebound quicker
competitor bound dme channel
link recent survey note
april endo survey april edit heavier relianc telem earli sign
march survey endocrinologist heavi telemedicin use like allay
declin patient visit
biomed devic servic
given durabl recur revenu model robust instal base
patient expect rel line consensu
expect though pocket weak ou two week soft
us elimin opportun upsid new patient add
encourag survey respons regard increas interest cgm
someth reinforc cgm first thesi like boost covid
social distanc rise telemedicin given abil clinician
seamlessli interact glucos data via multitud softwar applic
regardless expect new patient add challeng global go-forward
basi durat given econom uncertainti strain
provid resourc like serv headwind least
multipl articl press tout cgm tool hospit covid
patient hospit use long opportun though pale
comparison broader opportun may serv pull forward
use case said expect limit impact revenu
covid-rel disrupt like pose threat regulatori
commerci timelin given challeng outright inabl conduct
clinic trial right timelin risk extend sever
weve note increas interest investor respect index momentum
specif ad nasdaq index announc
effect result meet criteria
short-term set-up dynam social distanc serv highlight
util cgm provid patient clinician regardless feel like
like get reset expect call given impact covid
patient volum said expect dynam better appreci
investor current sell-sid estim reflect expect conserv
adjust guidanc read beatabl swift estim revis return
fundament execut adjust post-covid landscap
long-term fundament one best posit compani across
coverag univers cgm sit intersect nearli everi key theme
health/wel big-data/connect importantli leader
cgm best-in-class sensor platform increasingli robust softwar engin
patient/caregiv clinician strong brand within core
diabet market see long tailwind global adopt within core insulin
intens market expect see util market non-
intens pre-diabet gestat in-hospit begin ramp
sensor platform roll given recur natur userbas
expans strong margin profil high rang expect
core hold growth investor high shop list see anoth
market pullback next sever month
comment valuat quickli rebound march low
nearli expens across everi measur time period howev
see myriad reason expect investor look past near-term
uncertainti covid present focu lt opportun stick
playbook remain buy sharpen pencil valuat
scenario analys dust settl
biomed devic servic
weve rebuilt entir model introduc new revenu build ahead
result specif transit revenu build reflect
annual revenu per patient model rather histor build broke
revenu specif product sensor transmitt receiv believ
in-lin build guidanc structur contract
payor well reflect busi look
launch obviat need transmitt break revenu
payer/channel commerci dme commerci pharmaci medicar
lower revenu estim primarili base lower
expect new patient addit model revenu
guidanc call
modestli reduc oper spend expect near-term
invest delayed/postpon
valuat price target high-growth medic devic comp group
current trade ev/sal appli premium given
diabet industri insul cgm particular impact rel
sub-industri within med-tech sum rais price target
price target base ev/sal multipl appli sale estim
assum cash debt
share outstand valuat
figur summari chang estim
except ep newold newold newold revenu comp ev/sal multipl price metric use ev/sal valuat growth medic devic ev/sal multipl sale share outstand
biomed devic servic
benefit robust instal base recur revenu model
howev similar expect result in-lin slightli softer
current estim weak lower new patient
start impact forward growth
given onboard process pump includ clinician pump
program well patient train expect social distanc requir
materi impact new patient start next sever quarter time
expect clinician manufactur develop altern model streamlin
onboard process expect patient training/support bottleneck
forese futur
believ transit pharmaci channel uniqu posit
period covid disrupt push pharmaci channel
occur launch dash addit lower cost also elimin
major structur barrier patient onboard make insur
adjud near-inst process vers arduou week manual process
dme channel notabl pharmaci channel also elimin need
fast c-peptid test one major hurdl patient
result impress adopt date popul
covid-rel disrupt like pose threat horizon regulatori
commerci timelin given challeng outright inabl conduct
clinic trial right remind announc earli march
horizon pivot trial temporarili paus fix softwar anomali
like push commerci time earli trial expect
restart earli may howev believ timelin risk
europ repres one bigger near-term growth opportun
manag guid expand five addit countri
emea region given disrupt europ expect effort
like delay earliest
short-term set-up enough near-term risk insulet execut
wed prefer let compani print result reassess thesi
backdrop expect reset expect
long-term fundament continu view podd underli busi
commerci opportun manag execut collect one
best coverag univers strongli believ disrupt opportun
present shift pharmaci maintain hold given think
current valuat reflect recent execut someth
believ appropri reflect uncertainti regard econom
backdrop impact social distanc like near-term pump patient
addit hope get better entri point see anoth market pullback
next sever month
comment valuat quickli rebound march low
almost trade sale estim continu
view lt opportun posit think risk/reward balanc
level particularli given expect challeng period new
patient addit entir pump sector least
biomed devic servic
lower revenu estim primarili base lower
expect new patient addit model revenu
previous guidanc call
modestli reduc gross margin leverag expect lower unit
volum slower ramp product new acton manufactur line
serv headwind least
slightli reduc oper spend expect near-term
invest delayed/postpon
valuat high-growth medic devic comp group current
trade ev/sal appli premium given diabet insul
impact rel sub-industri within med-tech sum
maintain price target price target base ev/sal
multipl appli sale estim assum
cash debt share outstand valuat
figur summari chang estim
except ep newold newold newold revenu breakdownu comp group ev/sal multipl price metric use ev/sal valuat analysishigh growth medic devic sale share outstand biomed devic servic
figur februari present stock perform vs benchmark
factset compani report canaccord genuiti estim past perform predict futur result
figur trough march present stock perform vs benchmark
factset compani report canaccord genuiti estim past perform predict futur result
feb present stock perform vs benchmarksindividu return spi russel iwm ishar medic devic etf march present stock perform vs benchmarksindividu return spi russel iwm ishar medic devic etf ihi biomed devic servic
factset compani report canaccord genuiti estim past perform predict futur result
chang stock price sinc ipo inmd snn inmd
biomed devic servic
compani report canaccord genuiti estim detail financi model includ balanc sheet incom statement cash flow project avail may obtain contact canaccord genuiti sale person author analyst whose contact
inform appear front page report
biomed devic servic
biomed devic servic
compani report canaccord genuiti estim detail financi model includ balanc sheet incom statement cash flow project avail may obtain contact canaccord genuiti sale person author analyst whose contact
inform appear front page report
-- quarterli incom statementcanaccord genuiti kyle except omnipod neighborhood y/i chang q/q oper incom expens tax incom discontinu income/ loss continu share analysisoveral gross growthu omnipod growthu omnipod figur revenu build
biomed devic servic
 revenu buildcanaccord genuiti kyle us drug deliveri neighborhood y/i growth us drug deliveri q/q growth us drug deliveri biomed devic servic
